A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations
Sponsor: Immunovia, Inc.
This observational or N/A phase trial investigates FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome and Familial Pancreatic Cancer and is currently completed. Immunovia, Inc. leads this study, which shows 19 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2022 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Dec 2021 — Apr 2022 [monthly]
Active Not Recruiting
▶ Show 14 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting
-
May 2020 — Nov 2020 [monthly]
Recruiting
-
Mar 2020 — May 2020 [monthly]
Recruiting
-
Jan 2020 — Mar 2020 [monthly]
Recruiting
-
Oct 2019 — Jan 2020 [monthly]
Recruiting
-
Aug 2019 — Oct 2019 [monthly]
Recruiting
-
Jun 2019 — Aug 2019 [monthly]
Recruiting
-
Feb 2019 — Jun 2019 [monthly]
Recruiting
-
Dec 2018 — Feb 2019 [monthly]
Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Recruiting
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Immunovia, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .